Abstract
Background and Aims: Bempedoic acid (an ATP citrate lyase inhibitor) has recently been licensed for the treatment of dyslipidaemia in patients who are intolerant of statins. We aimed to assess if the tolerability and efficacy seen in clinical trials could be replicated in statin-intolerant patients in routine clinical practice.
Methods: Fifteen patients with high cardiovascular risk and statin intolerance were offered bempedoic acid 180mg once daily as monotherapy (N=3) or in combination with ezetimibe 10mg once daily (N=12). Fourteen were being treated as primary prevention and one as secondary prevention. They were reviewed after approximately three months of treatment to assess tolerability and lipid-lowering effect.
Results: At review, five patients has stopped taking bempedoic acid reporting side-effects similar to those experienced with statins. Ten patients reported that they were continuing with treatment (67 % tolerance rate). Lipid profiles demonstrated no LDL reduction in two patients, raising questions of treatment adherence. However in the eight patients who did experience a fall in LDL-cholesterol, mean reduction was 1.5 mmol/L (32.3%). Both the rate of tolerability and the average fall in LDL seen in our patients are comparable to what has been seen in clinical trials.
Conclusions: Clinical trial data cannot always be replicated in real-world practice, particularly when it concerns issues such as adverse effects and treatment adherence. However our data on our early experience with this agent confirm it as a useful additional option for clinicians managing hyperlipidaemia.
Methods: Fifteen patients with high cardiovascular risk and statin intolerance were offered bempedoic acid 180mg once daily as monotherapy (N=3) or in combination with ezetimibe 10mg once daily (N=12). Fourteen were being treated as primary prevention and one as secondary prevention. They were reviewed after approximately three months of treatment to assess tolerability and lipid-lowering effect.
Results: At review, five patients has stopped taking bempedoic acid reporting side-effects similar to those experienced with statins. Ten patients reported that they were continuing with treatment (67 % tolerance rate). Lipid profiles demonstrated no LDL reduction in two patients, raising questions of treatment adherence. However in the eight patients who did experience a fall in LDL-cholesterol, mean reduction was 1.5 mmol/L (32.3%). Both the rate of tolerability and the average fall in LDL seen in our patients are comparable to what has been seen in clinical trials.
Conclusions: Clinical trial data cannot always be replicated in real-world practice, particularly when it concerns issues such as adverse effects and treatment adherence. However our data on our early experience with this agent confirm it as a useful additional option for clinicians managing hyperlipidaemia.
| Original language | English |
|---|---|
| Pages (from-to) | 220 |
| Number of pages | 1 |
| Journal | Atherosclerosis |
| Volume | 355 |
| DOIs | |
| Publication status | Published - 30 Aug 2022 |
| Externally published | Yes |